Effect of Topiramate on Apoptosis-related Protein Expression of Hippocampus in Model Rats with Alzheimers Disease
Overview
Pharmacology
Toxicology
Affiliations
Objectives: Alzheimer's disease is an age-related neurodegenerative disease and a synaptic function defect disease, the clinical symptoms are mainly progressive cognitive impairment, affecting patient's social function. Aim of this report was to investigate the effect of topiramate on apoptosis-related protein expression (Bcl-2, Survivin, Fas, Bax and Caspase-3) in the hippocampus of a rat model with Alzheimers Disease (AD).
Materials And Methods: Thirty-six adult Wistar rats were randomly divided into a control group, a model group and a test group. A dose of amyloid beta-protein 1-40 (Aβ1-40) was injected into the hippocampus of the rats in the model and test groups, and the control rats are injected with same amount of saline. After AD model was successfully established, the rats in each group were administrated with an i.p. injection of topiramate (20 mg/kg/d) for 30 days. The effect of topiramate on the apoptosis-related protein levels in hippocampus neurons was studied by immunohistochemistry.
Results: The number of Bcl-2 and Survivin positive cells and optical density in hippocampus of rats in test group was more than those of rats in model groups, but less than those of rats in control group (p < 0.01); Fas, Bax and Caspase-3 positive cells and optical density in hippocampus of rats in test group was less than those of rats in the model group, but more than those of rats in control group (p < 0.01).
Conclusions: Alzheimer's disease can induce apoptosis of hippocampus neurons in rats. Topiramate can prevent apoptosis of hippocampus neurons, at least in part, by increasing expression of Bcl-2 and Survivin and decreasing expression of Fas, Bax and Caspase-3.
Antiseizure Medications in Alzheimer's Disease from Preclinical to Clinical Evidence.
Bosco F, Guarnieri L, Rania V, Palma E, Citraro R, Corasaniti M Int J Mol Sci. 2023; 24(16).
PMID: 37628821 PMC: 10454935. DOI: 10.3390/ijms241612639.
Chaibi I, Ait-Mansour I, Tari M, Bennis M, Ba-Mhamed S Psychopharmacology (Berl). 2023; 240(7):1473-1492.
PMID: 37217572 DOI: 10.1007/s00213-023-06381-z.
Arab H, Abd El Aal H, Alsufyani S, El-Sheikh A, Arafa E, Ashour A Pharmaceuticals (Basel). 2022; 15(11).
PMID: 36422532 PMC: 9697422. DOI: 10.3390/ph15111402.
Jameie S, Pirasteh A, Naseri A, Jameie M, Farhadi M, Babaee J Basic Clin Neurosci. 2021; 12(3):383-394.
PMID: 34917297 PMC: 8666925. DOI: 10.32598/bcn.2021.2634.1.
Owona B, Zug C, Schluesener H, Zhang Z Int J Mol Sci. 2019; 20(12).
PMID: 31248209 PMC: 6628361. DOI: 10.3390/ijms20123003.